NovoMix 30

NovoMix 30

insulin aspart + insulin aspart protamine

Manufacturer:

Novo Nordisk

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Per 100 U/mL Insulin aspart (30% as soluble insulin aspart; 70% as protamine crystallised insulin aspart)
Dosage/Direction for Use
Individualized dosage. SC Type 2 diabetes Monotherapy or in combination w/ OAD when blood glucose is inadequately controlled w/ oral antidiabetic drugs alone: Initially 6 U bd in the morning & evening. Alternatively 12 U once daily in the evening. When using once daily, it is recommended to increase to bd when reaching 30 U by splitting the dose into equally divided doses (morning & evening). If bd-dosing results in recurrent daytime hypoglycaemic episodes, the morning dose can be divided into morning & midday doses (tds-dosing).
Administration
May be taken with or without food: Administer immediately before or soon after a meal.
Contraindications
Special Precautions
Travelling between different time zones may require change in timing of dosing & meals. Inadequate dosing or discontinuation of treatment may lead to hyperglycemia & diabetic ketoacidosis. Avoid omission of a meal or unplanned strenuous physical exercise. Concomitant diseases or medication that delays food absorption. Concomitant illness (especially infections). Concomitant diseases of kidney, liver, adrenal, pituitary or thyroid gland. Careful in switching to a new type or brand of insulin. Continuous rotation of inj site w/in a given area to reduce inj site reactions. Dose adjustment in case of insulin antibodies. May affect the ability to drive or operate machinery in case of hypoglycaemia. Pregnancy & lactation. Childn <9 yr. Elderly >75 yr.
Adverse Reactions
Hypoglycemia, urticaria, rash, eruptions, refraction disorders, diabetic retinopathy, lipodystrophy, inj site reactions, oedema, peripheral neuropathy, anaphylactic reactions.
Drug Interactions
May develop heart failure w/ thiazolidinediones. May reduce insulin requirements w/ oral hypoglycaemic agents, MAOIs, β-blockers, ACE inhibitors, salicylates, anabolic steroids & sulphonamides. May increase insulin requirements w/ OC, thiazides, glucocorticoids, thyroid hormones, sympathomimetics, growth hormone & danazol. May mask symptoms of hypoglycaemia w/ β-blockers. May increase/decrease insulin requirement w/ octreotide/lanretotide. May intensify & reduce hypoglycaemic effect w/ alcohol.
MIMS Class
Insulin Preparations
ATC Classification
A10AD05 - insulin aspart ; Belongs to the class of intermediate-acting combined with fast-acting insulins and analogues. Used in the treatment of diabetes.
Presentation/Packing
Form
NovoMix 30 FlexPen
Packing/Price
3 mL x 5 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in